ScholarLens Back to search
2019•PULMONOLOGIYAOpen access

Triple therapy in chronic obstructive pulmonary disease

Sergey Nikolaevich Avdeev, Н В Трушенко

Open full text 11 citations

Abstract

Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.

Open-access reader

About this research paper

What this paper is about

Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Recently, therapeutic options for treatment of chronic obstructive pulmonary disease (COPD) has been significantly extended, mainly due to new double and triple drug combinations in a single inhaler. Double combinations for treatment of COPD include long-term acting beta-2-agonists (LABA)/long-term acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroids (ICS); a triple combination is a combination of LABA, LAMA and ICS in a single inhaler. A review of consensus statements, national guidelines and recently published data about use of triple therapy in COPD, efficacy and safety of a triple combination is given in the article.

Key concepts: Lama, Medicine, COPD, Inhaler, Pulmonary disease, Intensive care medicine, Internal medicine, Asthma

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Triple therapy in chronic obstructive pulmonary disease — Research Paper | ScholarLens